GSK to Acquire RAPT Therapeutics for $2.2 Billion at $58 Share
GSK’s $2.2B acquisition of RAPT Therapeutics, priced at $58.00 per share, secures ozureprubart, a Phase 2b anti-IgE antibody for food allergy prophylaxis. The deal implies a notable premium to RAPT’s share price and underscores GSK’s strategic investment in immunological therapies.
1. Acquisition Terms
In January, GSK agreed to acquire RAPT Therapeutics at $58.00 per share in an all-cash transaction valuing the company’s equity at approximately $2.2 billion. The acquisition price represents a significant premium to RAPT’s pre-announcement trading levels and was structured under a definitive merger agreement.
2. Lead Pipeline Asset
The acquisition secures ozureprubart, a long-acting anti-immunoglobulin E monoclonal antibody currently in Phase 2b clinical development for prophylactic protection against food allergens. This candidate targets IgE-mediated allergic responses and positions GSK to advance into potential late-stage trials in the food allergy market.
3. Strategic Implications
The $2.2 billion takeover underscores GSK’s commitment to expanding its immunology and allergy portfolio with late-stage biologics. For RAPT shareholders, the deal provides immediate cash value and removes standalone development risk, while GSK gains a differentiated candidate to bolster its specialty medicines pipeline.